Clinical

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.

One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.

Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, highlighting the urgent need for providers to address the escalating impacts of climate change on lung health.

Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in patients with heart failure with reduced ejection fraction (HFrEF), while also addressing prescription barriers for providers.

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex with men.

This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of chronic obstructive pulmonary disease (COPD), with better adherence and outcomes among those using single-inhaler triple therapy.

CNTN1 and NRXN3 clearly differentiated severe and milder forms of spinal muscular atrophy (SMA).

A poster presented at the CHEST 2024 annual meeting shows that inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD).

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin thickening in atopic dermatitis, and increased risk of cardiovascular issues and metabolic disorders.

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive pulmonary disease (COPD).

At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to address issues like air pollution and health equity in respiratory care.

Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).

Recent results from a new diabetes reversal program demonstrate the reliable, sustained benefits of nonpharmacological interventions in the management of diabetes and overall health of patients.